Advertisement

Topics

Latest "Panobinostat And Epirubicin In Treating Patients With Metastatic Malignant Solid Tumors" News Stories - Page: 4

21:53 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Panobinostat And Epirubicin In Treating Patients With Metastatic Malignant Solid Tumors" found in our extensive news archives from over 250 global news sources.

More Information about Panobinostat And Epirubicin In Treating Patients With Metastatic Malignant Solid Tumors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Panobinostat And Epirubicin In Treating Patients With Metastatic Malignant Solid Tumors for you to read. Along with our medical data and news we also list Panobinostat And Epirubicin In Treating Patients With Metastatic Malignant Solid Tumors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Panobinostat And Epirubicin In Treating Patients With Metastatic Malignant Solid Tumors Companies for you to search.

Showing "Panobinostat Epirubicin Treating Patients With Metastatic Malignant Solid" News Articles 76–100 of 23,000+

Thursday 21st March 2019

Antibiotics, PPIs Tied to Higher C. Diff Risk in Hospitalized Children

THURSDAY, March 21, 2019 -- Previous antibiotic exposure and use of proton pump inhibitors (PPIs) may be risk factors for Clostridioides (formerly Clostridium) difficile infection (CDI) in hospitalized pediatric patients, according to a review...


Drug-Free Wireless Pain Relief Neurostimulator Changing Lives for Sufferers of Chronic Pain

World’s First Wireless, Miniature Implantable Long-Term Therapy Breakthrough now available in Canada Statistics Canada says six million people across the country suffer from chronic pain, meaning about 20 per cent of the population is affected. Everyone knows someone suffering from chronic pain and how debilitating it can be, but neurostimulation is ...

ZipLine Medical Announces New Emergency Department Study Showing Significant Time and Cost Savings, and Superior Patient Satisfaction, with Laceration Closure Using Zip® Surgical Skin Closure

ZipLine Medical, Inc. today announced presentation of positive results from a randomized, prospective clinical study conducted at the Karolinska University Hospital in Stockholm, Sweden demonstrating both clinical and economic benefits of the Zip® Surgical Skin Closure device when used in an emergency medicine setting for lacerations. A poster...


Drug Safety and Tolerability in New Transplant Therapies

A new position statement from the Transplant Therapeutics Consortium stresses the importance of considering the safety and tolerability of new therapeutic options for transplant patients. American Journal of Transplantation

Program Improves Communication Between Oncology Clinicians and Patients

The Serious Illness Care Program helps oncologists have better serious-illness conversations with patients without creating anxiety or depression, according to results of a cluster-randomized clinical trial. Reuters Health Information

Biogen and Eisai discontinue Phase 3 Alzheimer's trial

Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease. The decision came after analysis found the trials were unlikely to meet their primary endpoint upin completion. The recommendation to end the trials was not based on safety concerns. read more

Minimally Invasive TMJ Arthroscopy Offered by Acclaimed Oral Surgeons in Dana Point, CA for Jaw Pain Relief

Dr. Eric Baker and Dr. Tim Betita, acclaimed oral surgeons at Niguel Coast Oral and Facial Surgery, invite patients suffering from TMJ disorder-related jaw pain in Dana Point, CA, to consider the value and benefits of an advanced TMJ arthroscopy when other treatments are ineffective. DANA POINT, Calif. (PRWEB) March 21, 2019 Highly trained and credentialed oral surgeons Dr. Eric Baker and Dr. Tim...

EMA publishes safety warning for Pfizer’s Xeljanz in rheumatoid arthritis

The European Medicines Agency (EMA) has advised patients and clinicians to not exceed the 5mg twice daily recommendation dose of...Read More... The post EMA publishes safety warning for Pfizer’s Xeljanz in rheumatoid arthritis appeared first on Pharmaceutical Technology.

Liquid Biopsy Spots Early Liver Cancer in Patients With HBV Infection

In high-risk patients with asymptomatic hepatitis B virus (HBV) infection, a liquid biopsy shows promise in detecting early-stage hepatocellular carcinoma (HCC), according to Chinese and U.S. researchers. Reuters Health Information

Diaceutics PLC makes strong start on London's AIM debut

Peter Keeling, chief executive of data analytics firm Diaceutics PLC (LON:DXRX), speaks to Proactive London's Andrew Scott as the firm began trading on London's AIM market. The group collects laboratory, anonymised patient, and insurance claims data which it then provides to pharmaceutical companies to help them reach more patients who need to be on certain, specific drugs. Diaceutics curren...

Theratechnologies And NASH In HIV Patients, And The Market Assessment

Aducanumab was always a binary bet for Biogen - and a big one. I personally believed it was worth making, though was in a vanishing minority in that position. I guess I'm not surprised. But I am deeply disappointed for present and future patients.

Aducanumab was always a binary bet for Biogen - and a big one. I personally believed it was worth making, though was in a vanishing minority in that position. I guess I'm not surprised. But I am deeply disappointed for present and future patients.

Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treat...

Teleflex Announces Real-World Data Demonstrating the Effectiveness of the UroLift® System to Treat Patients with Enlarged Prostate

Findings Presented at European Association of Urology Show Consistent Positive Results for Minimally Invasive UroLift System Treatment Teleflex Incorporated (NYSE:TFX) today announced that multiple studies were presented at the 2019 European Association of Urology (EAU) meeting in Barcelona, Spain, highlighting the effectiveness of the UroLift® System...

FORMA Therapeutics Announces Frank D. Lee as Chief Executive Officer

FORMA Therapeutics announced today the appointment of Frank D. Lee as Chief Executive Officer, starting on March 27, 2019. Frank succeeds Steve Tregay, Ph.D., who after more than a decade as Founder and CEO, will transition to the role of Senior Advisor to the CEO. Frank, an industry veteran and champion for patients, joins FORMA with over 25 years of glob...

Not OK: When Patients Sexually Harass Physicians

(MedPage Today) -- A common yet rarely discussed abuse

Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in an or...

FDA Clears Solriamfetol (Sunosi) for Narcolepsy, OSA

The dual-acting dopamine and norepinephrine reuptake inhibitor showed durable effects in reducing excessive sleepiness in patients with narcolepsy or obstructive sleep apnea. Medscape Medical News

Novocure’s Chief Science Officer Retires after 17 Years of Service

Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family. “While this was a difficult decision, it is the ri...

Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical tri...

Rare Diseases: PKU GOLIKE® Debuts in Germany

PKU GOLIKE®, the brand new generation of Phenylalanine (PHe)-free medical food for Phenylketonuria (PKU) dietary management, is now available in Germany and Austria, promoted and distributed directly by APR Applied Pharma Research s.a. (APR) through its local subsidiary, APR Deutschland. The company has taken advantage of the 33th Annual Meeting ...

AGH Study Advances Tool Used in Determining Treatment for Patients with Pulmonary Arterial Hypertension

Based on results of a research conducted at Allegheny General Hospital, the REVEAL 2.0 risk score calculator is expected to become the most commonly used risk prognostic tool for patients suffering from pulmonary arterial hypertension. PITTSBURGH, Pa. (PRWEB) March 21, 2019 A study conducted by researchers at Allegheny General Hospital (AGH), part of Allegheny Health Network (AHN), has demonstrat...

Allergan Announces FDA Approval of AVYCAZ for Pediatric Patients

NewsThe FDA has approved the company's supplemental New Drug Application for AVYCAZ® for the treatment of complicated intra-abdominal infections.

Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial

--Study will test efficacy and safety of novel docetaxel-based oral therapeutic-- Modra Pharmaceuticals B.V. (“Modra”) today announced that the first patients have been treated in its Phase IIa study in patients with recurrent or metastatic HER-2 negative breast cancer. The trial will evaluate the efficacy and safety of Modra’s lead product, Modr...

AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S.

LAUSANNE, Switzerland, March 21, 2019 / B3C newswire / -- AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced today that a single-arm open label design with a randomized withdrawal phase for its ongoing pivotal Phase 3 trial under an Investigational New Drug (IND) App...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks